Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina develops DNA sequencing, array-based, informatics and proteomics technologies for research, clinical and applied markets. Company news commonly covers sequencing instruments and consumables, NovaSeq X demand, DRAGEN software releases, TruPath Genome analytical support, and applications in oncology, reproductive health, agriculture, rare disease and drug discovery.
Illumina updates also include collaborations around precision oncology testing, preventive and population genomics, pediatric cancer and rare disease data, and the Alliance for Genomic Discovery. Financial and corporate news covers revenue trends, operating margins, earnings guidance, share repurchase authorizations, acquisitions in multiomics and proteomics, and board or management changes.
Illumina (NASDAQ:ILMN) announced that its executives will speak at the J.P. Morgan Virtual Healthcare Conference on January 11, 2021. The presentation is scheduled for 11:00 AM Pacific Time, followed by a Q&A session starting at approximately 11:20 AM. Investors can access the live webcast under the Investor Info section on www.illumina.com. Replays will be available for at least 30 days after the event. Illumina is a leader in DNA sequencing, focusing on innovations that enhance human health across various markets, including oncology and reproductive health.
Illumina and Harvard Pilgrim Health Care have entered a risk-sharing agreement to provide whole-genome sequencing (WGS) to select members, starting January 1, 2021. This initiative aims to expedite the diagnosis of genetic disorders in pediatric patients, potentially alleviating lengthy and expensive diagnostic processes that can exceed $20,000. The partnership is grounded in over 20 peer-reviewed studies showing WGS's clinical effectiveness in over 3,000 patients. Both organizations will evaluate the impact of WGS on healthcare expenses while working to enhance patient outcomes.
Illumina (NASDAQ:ILMN) announces its executives will present at the Piper Sandler Annual Healthcare Conference on December 3, 2020, at 1:30 PM Eastern Time. Interested investors can participate via a live webcast available in the Investor Info section of Illumina's website. The replay will be accessible for 30 days post-event. Illumina leads in DNA sequencing and array-based technologies, focusing on enhancing human health through innovative genomic solutions. For more details, visit www.illumina.com.
Illumina (NASDAQ: ILMN) has launched the P3 high-output flow cell for its NextSeq 2000 Sequencing System, significantly enhancing its sequencing capabilities. This new flow cell offers 1.1 billion reads per run, nearly tripling the output of previous models. It is expected to empower researchers by expanding project potential while optimizing costs. The NextSeq 1000, with a more accessible price for 400 million reads, is also available, featuring rapid analysis and cloud-based technology. These developments aim to simplify workflows and foster innovation across genomics.
Illumina presents the commercial launch of the P3 high-output flow cell for its NextSeq 2000 Sequencing System, significantly enhancing throughput with 1.1 billion reads per run. This innovation expands application versatility and provides customers with cost-effective solutions for deeper genomic insights. The NextSeq 1000 and 2000 systems incorporate advanced informatics and cloud-based genomic compression technology, further optimizing the sequencing process. This rollout indicates a strategic move to strengthen market position by offering affordable pricing and operational efficiency.
Illumina, Inc. (NASDAQ:ILMN) is set to announce its third-quarter 2020 results post-market on October 29, 2020. Following the results, a conference call will be held at 2:00 PM PT (5:00 PM ET) featuring CEO Francis deSouza and CFO Sam Samad, who will discuss financial and operational outcomes. Interested participants can join via Illumina's website or by dialing in. A replay of the call will be available for 30 days afterward.
Illumina Ventures has announced the promotion of Wouter Meuleman to Partner. Meuleman, previously a Principal, was integral to early investments in companies such as Biota Technology, Inc. and Delfi Genomics, Inc. His background includes nine years at Illumina, where he focused on venture investing and technology acquisitions. Illumina Ventures aims to support innovative genomics companies and is committed to advancing biotechnology, especially in light of heightened public health awareness.